| abstract |
It is tried to produce an antibody capable of neutralizing the activity of a substance having an activity alternative to the function of FVIII, for the purpose of using the antibody in a method for measuring the reactivity of FVIII in the presence of the substance having the activity alternative to the function of FVIII. As the result, it is found that, when the produced antibody is used, the activity of FVIII in plasma from a hemophilia A patient can be evaluated accurately in an APTT-based one-stage clotting assay. It is also found that, when the produced antibody is used, the titer of an FVIII inhibitor in plasma from an FVIII inhibitor-carrying hemophilia A patient can be evaluated accurately in an APTT-based Bethesda assay. |